Skip to main content

Branch Atheromatous Disease

1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
TirofibanPhase 3
Pharmaron
PharmaronRI - Coventry
1 program
TirofibanPHASE_31 trial
Active Trials
NCT06037889Completed516Est. Feb 2026

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
PharmaronTirofiban

Clinical Trials (1)

Total enrollment: 516 patients across 1 trials

Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

Start: Nov 2023Est. completion: Feb 2026516 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.